摘要
目的分析美托洛尔+贝那普利对冠心病心力衰竭的治疗效果、心功能改善情况。方法103例冠心病心力衰竭患者,随机分为研究组(52例)与对照组(51例)。研究组采用美托洛尔+贝那普利治疗,对照组采用美托洛尔治疗。比较两组的治疗效果、心功能指标[左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、左室收缩末期直径(LVESD)]、同型半胱氨酸(Hcy)、C反应蛋白(CRP)、胱抑素C(Cys C)、脑利钠肽(BNP)、不良反应发生情况、血液流变学指标[血浆粘度(ηp)、全血粘度(ηb)、纤维蛋白原(Fib)、血沉(ESR)]。结果研究组的治疗总有效率94.23%高于对照组的74.51%,差异具有统计学意义(P<0.05)。治疗后,研究组LVEDD(45.92±10.83)mm、LVESD(32.62±11.23)mm均短于对照组的(51.01±10.34)、(40.97±11.15)mm,LVEF(55.36±10.06)%高于对照组的(47.26±11.23)%,差异具有统计学意义(P<0.05)。治疗后,研究组CRP(12.26±3.16)mg/L、Hcy(14.03±1.06)μmol/L、BNP(548.36±113.52)pg/ml、Cys C(4.52±1.23)mg/L均显著低于对照组的(17.15±4.08)mg/L、(16.02±2.83)μmol/L、(695.68±128.64)pg/ml、(7.03±1.29)mg/L,差异具有统计学意义(P<0.05)。研究组不良反应发生率5.77%低于对照组的17.65%,但差异无统计学意义(P>0.05)。治疗后,研究组ηp(1.27±0.19)mPa·s、ηb(4.12±0.26)mPa·s、Fib(3.31±0.42)g/L、ESR(14.06±4.02)mm/h均显著低于对照组的(1.91±0.11)mPa·s、(5.03±0.43)mPa·s、(3.95±0.54)g/L、(23.18±3.84)mm/h,差异具有统计学意义(P<0.05)。结论美托洛尔+贝那普利对冠心病心力衰竭的治疗效果显著,可有效改善患者心功能水平及血液流变学指标,临床疗效确切,且安全可靠,有临床应用的意义。
Objective To analyze the effect of metoprolol and benazepril on coronary heart disease with heart failure and its influence on improvement of cardiac function.Methods A total of 103 patients with coronary heart disease with heart failure were randomly divided into the research group(52 cases)and the control group(51 cases).The research group was treated with metoprolol and benazepril,and the control group was treated with metoprolol.Both groups were compared in terms of therapeutic effect,cardiac function indexes[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)],homocysteine(Hcy),C-reactive protein(CRP),cystatin C(Cys C),brain natriuretic peptide(BNP),occurrence of adverse reactions,hemorheology indicators[plasma viscosity(ηp),whole blood viscosity(ηb),fibrinogen(Fib),erythrocyte sedimentation rate(ESR)].Results The total effective rate 94.23%of the research group was higher than 74.51%of the control group,and the difference was statistically significant(P<0.05).After treatment,the LVEDD(45.92±10.83)mm and LVESD(32.62±11.23)mm in the research group were shorter than(51.01±10.34)and(40.97±11.15)mm in the control group,and the LVEF(55.36±10.06)%was higher than(47.26±11.23)%in the control group.All the differences were statistically significant(P<0.05).After treatment,the CRP(12.26±3.16)mg/L,Hcy(14.03±1.06)μmol/L,BNP(548.36±113.52)pg/ml,Cys C(4.52±1.23)mg/L in the research group were significantly lower than(17.15±4.08)mg/L,(16.02±2.83)μmol/L,(695.68±128.64)pg/ml,and(7.03±1.29)mg/L in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions 5.77%in the research group was lower than 17.65%in the control group,but the difference was not statistically significant(P>0.05).After treatment,theηp(1.27±0.19)mPa·s,ηb(4.12±0.26)mPa·s,Fib(3.31±0.42)g/L and ESR(14.06±4.02)mm/h in the research group were significantly lower than(1.91±0.11)mPa·s,(5.03±0.43)mPa·s,
作者
王淑杰
WANG Shu-jie(Central Hospital of Kazuo County,Chaoyang 122300,China)
出处
《中国实用医药》
2022年第20期41-44,共4页
China Practical Medicine
关键词
冠心病心力衰竭
美托洛尔
贝那普利
治疗效果
心功能指标
血液流变学
Coronary heart disease with heart failure
Metoprolol
Benazepril
Therapeutic effect
Cardiac function index
Hemorheology
